Based on the ATAI Life Sciences BV stock forecast from 0 analysts, the average analyst target price for ATAI Life Sciences BV is not available over the next 12 months. ATAI Life Sciences BV’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ATAI Life Sciences BV is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, ATAI Life Sciences BV’s stock price was USD 1.37. ATAI Life Sciences BV’s stock price has changed by +1.48% over the past week, +24.55% over the past month and +9.16% over the last year.
No recent analyst target price found for ATAI Life Sciences BV
No recent average analyst rating found for ATAI Life Sciences BV
Company Overview ATAI Life Sciences BV
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London. Address: Wallstrasse 16, Berlin, Germany, 10179 Read Less
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 progr...Read More
Frequently Asked Questions About ATAI Life Sciences BV (ATAI) Stock
Stock Target Advisor's fundamental analysis for ATAI Life Sciences BV's stock is Neutral.
Unfortunately we do not have enough data on ATAI's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ATAI's stock to indicate what its average analyst target is.
ATAI stock's Price/Earning ratio is 0.30.
Our analysis grades ATAI stock's Price / Earning ratio at C+. This means that ATAI stock's Price/Earning ratio is above 21% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ATAI may be undervalued for its sector.
The last closing price of ATAI's stock was USD 1.37.
The most recent market capitalization for ATAI is USD 0.23B.
Unfortunately we do not have enough analyst data on ATAI's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ATAI Life Sciences BV's stock.
As per our most recent records ATAI Life Sciences BV has 83 Employees.
ATAI Life Sciences BV's registered address is Wallstrasse 16, Berlin, Germany, 10179.
You can get more information about it from ATAI Life Sciences BV's website at https://www.atai.life.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About ATAI Life Sciences BV (ATAI) Stock
Stock Target Advisor's fundamental analysis for ATAI Life Sciences BV's stock is Neutral.
Unfortunately we do not have enough data on ATAI's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ATAI's stock to indicate what its average analyst target is.
ATAI stock's Price/Earning ratio is 0.30.
Our analysis grades ATAI stock's Price / Earning ratio at C+. This means that ATAI stock's Price/Earning ratio is above 21% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ATAI may be undervalued for its sector.
The last closing price of ATAI's stock was USD 1.37.
The most recent market capitalization for ATAI is USD 0.23B.
Unfortunately we do not have enough analyst data on ATAI's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ATAI Life Sciences BV's stock.
As per our most recent records ATAI Life Sciences BV has 83 Employees.
ATAI Life Sciences BV's registered address is Wallstrasse 16, Berlin, Germany, 10179.
You can get more information about it from ATAI Life Sciences BV's website at https://www.atai.life.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ATAI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
